An Excellent Network

Supporting the Development

of a Novel Drug Class

Deeply Rooted in the Biology and Chemistry of Epoxyeicosanoids

OMEICOS was founded based on ground-breaking scientific discoveries in the field of omega-3 fatty acid metabolism and physiology.

This research performed by the companies’ founders, Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer led to a rethinking of the omega-3 pathway and its therapeutic value in several indications with high unmet medical need. The scientific founders were joined by Dr. Karen Uhlmann, who brought valuable tech transfer expertise to the mix to launch and grow the company.

Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

John R. Falck

John R. Falck is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids.

John R. Falck

John R. Falck is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids.

Dominik Müller

Dominik N. Mueller is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 25 years of research experience in the field. His current work is focused on the crosstalk between immune cells, vasculature and target organs of hypertension. His research group’s major research interests are beside the understanding of pathomechanisms leading to cardiovascular disease, the identification of cardiovascular risk factors and new target for treatment.

Dominik Müller

Dominik N. Mueller is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 25 years of research experience in the field. His current work is focused on the crosstalk between immune cells, vasculature and target organs of hypertension. His research group’s major research interests are beside the understanding of pathomechanisms leading to cardiovascular disease, the identification of cardiovascular risk factors and new target for treatment.

Robert Fischer

Robert Fischer is a board-certified medical doctor in internal medicine and worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin. He has long-term professional experience as principle investigator and sub-investigator in several cardiovascular clinical trials. At Max-Delbrueck-Center for Molecular Medicine, Dr. Fischer led a research group and established methods to analyze arrhythmia mechanisms in animal models.

Robert Fischer

Robert Fischer is a board-certified medical doctor in internal medicine and worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin. He has long-term professional experience as principle investigator and sub-investigator in several cardiovascular clinical trials. At Max-Delbrueck-Center for Molecular Medicine, Dr. Fischer led a research group and established methods to analyze arrhythmia mechanisms in animal models.

Karen Uhlmann

Karen Uhlmann has more than 20 years experience in IP Asset Management, being instrumental in partnering a multitude of innovative technologies from academia to biotech and pharma companies, closing option and license agreements, raising funds, drafting and executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin.

Karen Uhlmann

Karen Uhlmann has more than 20 years experience in IP Asset Management, being instrumental in partnering a multitude of innovative technologies from academia to biotech and pharma companies, closing option and license agreements, raising funds, drafting and executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin.

Supported by Experienced External Consultants

Drug development is a complex and challenging discipline. In order to ensure that all aspects are addressed, OMEICOS benefits from an excellent network of highly experienced individuals in different fields of expertise.

Markus Henrich

Consultant Medicinal Chemistry and CMC
(Qemicon GmbH)

Qemicon is a specialist consulting company in the field of CMC and others. Markus Henrich, Managing Director of Qemicon, has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as Management Consultant he constantly supports a multitude of pharmaceutical companies in the field of Drug Discovery and Development. Areas of special expertise are Innovation Productivity and CMC. Qemicon provides consultancy services in all CMC related topics

Markus Henrich

Consultant Medicinal Chemistry and CMC
(Qemicon GmbH)

Qemicon is a specialist consulting company in the field of CMC and others. Markus Henrich, Managing Director of Qemicon, has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as Management Consultant he constantly supports a multitude of pharmaceutical companies in the field of Drug Discovery and Development. Areas of special expertise are Innovation Productivity and CMC. Qemicon provides consultancy services in all CMC related topics

Henk Streefkerk

Consultant Clinical Development
(Streefkerk Life Sciences Consultancy)

Henk Streefkerk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk will support the team in the overall clinical development of OMT-28

Henk Streefkerk

Consultant Clinical Development
(Streefkerk Life Sciences Consultancy)

Henk Streefkerk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk will support the team in the overall clinical development of OMT-28

Backed by a Committed Investor Consortium

OMEICOS has been successful in attracting a consortium of renowned healthcare investors and has been strongly supported by additional business angels, family offices and institutional investors. Since its inception in 2013, the company has received a total of EUR 35,5 million in private equity via three financing rounds and another EUR 4.4 million in non-dilutive funding from Federal Ministry of Education and Research – BMBF, and from Investitionsbank Berlin – IBB, via a seed funding grant.

ForbionVesaliusRemiges  High-Tech Gründerfonds KFW  Fogel-Falck TrustAscenionIBB BeteiligungsgesellschaftUT SouthwesternBundesministerium für Bildung und Forschung

Alliances Around Epoxyeicosanoid Biology to Unlock Full Therapeutic Potential

OMEICOS is committed to bringing novel therapeutics based on its proprietary approach to patients suffering from Cardiovascular Diseases as well as from other diseases, associated with inflammation and mitochondrial dysfunction. We are constantly looking to secure alliances along the different stages of drug development, in technology and research.

Max Delbrück Center in the Helmholtz Association

As a spin-off from the MDC Berlin, OMEICOS has continued a close collaboration with the working groups of OMEICOS’ co-founders Dr. Wolf-Hagen Schunck and Dr. Dominik Müller since its foundation. Joint research activities helped to further elucidate the molecular mode of action of natural Cytochrome P450-dependent metabolites of omega-3 fatty acids and their synthetic analogs activating a novel protective pathway in cardiomyocytes and other cell types.

Max Delbrück Center in the Helmholtz Association

As a spin-off from the MDC Berlin, OMEICOS has continued a close collaboration with the working groups of OMEICOS’ co-founders Dr. Wolf-Hagen Schunck and Dr. Dominik Müller since its foundation. Joint research activities helped to further elucidate the molecular mode of action of natural Cytochrome P450-dependent metabolites of omega-3 fatty acids and their synthetic analogs activating a novel protective pathway in cardiomyocytes and other cell types.

University of Alberta

OMEICOS is working closely together with the research group of John Seubert to investigate the effect of OMEICOS’ compounds in indications, associated with mitochondrial dysfunction. Dr. Seubert’s laboratory research is focused on investigating the role of CYP epoxygenase metabolites in maintaining tissue homeostasis and reducing injury with a special focus on cardioprotection, ischemia-reperfusion, mitochondria, toxicology, the cytochrome P450 system and mechanisms of cellular death.

University of Alberta

OMEICOS is working closely together with the research group of John Seubert to investigate the effect of OMEICOS’ compounds in indications, associated with mitochondrial dysfunction. Dr. Seubert’s laboratory research is focused on investigating the role of CYP epoxygenase metabolites in maintaining tissue homeostasis and reducing injury with a special focus on cardioprotection, ischemia-reperfusion, mitochondria, toxicology, the cytochrome P450 system and mechanisms of cellular death.

OMEICOS is working closely together with the research group of Dobromir Dobrev to investigate the effect of OMEICOS’ compounds on Calcium homeostasis and related signal transduction processes. Dr. Dobrev’s laboratory research is focused on clarifying how specific molecular alterations in cardiac cells and disease-related remodeling cause electrical instability.

OMEICOS is working closely together with the research group of Dobromir Dobrev to investigate the effect of OMEICOS’ compounds on Calcium homeostasis and related signal transduction processes. Dr. Dobrev’s laboratory research is focused on clarifying how specific molecular alterations in cardiac cells and disease-related remodeling cause electrical instability.

Lipidomix

Lipidomix GmbH is a specialized lipid analysis lab which conducts high-throughput lipidomic analysis, in particular eicosanoids. It is based on rapid-resolution-HPLC in combination with triple quad tandem mass spectrometry. Lipidomix develops and validates analysis methods for areas in the life sciences, food monitoring, forensics and others.

Lipidomix

Lipidomix GmbH is a specialized lipid analysis lab which conducts high-throughput lipidomic analysis, in particular eicosanoids. It is based on rapid-resolution-HPLC in combination with triple quad tandem mass spectrometry. Lipidomix develops and validates analysis methods for areas in the life sciences, food monitoring, forensics and others.

Omegametrix

Omegametrix is an international reference laboratory for the determination of the so called HS-Omega-3 Index®, a standardized method for erythrocyte fatty acid analysis. Dr. Clemens von Schacky, Head of Preventive Cardiology at the LMU Munich, together with Prof. W.S. Harris, Sanford University established the HS-Omega-3 Index® and founded Omegametrix in Martinsried, Germany, in 2007.

Omegametrix

Omegametrix is an international reference laboratory for the determination of the so called HS-Omega-3 Index®, a standardized method for erythrocyte fatty acid analysis. Dr. Clemens von Schacky, Head of Preventive Cardiology at the LMU Munich, together with Prof. W.S. Harris, Sanford University established the HS-Omega-3 Index® and founded Omegametrix in Martinsried, Germany, in 2007.

Biotronik

Biotronik is a leading medical device company that has been developing innovative cardiovascular and endovascular solutions for more than 50 years. Biotronik is headquartered in Berlin, Germany, and represented in over 100 countries. OMEICOS had implemented Biotronik’s insertable cardiac monitor BioMonitor 2 into the study design of the Phase 2 clinical trial of OMT-28 in persistent Atrial Fibrillation to accurately detect and monitor arrhythmias.

Biotronik

Biotronik is a leading medical device company that has been developing innovative cardiovascular and endovascular solutions for more than 50 years. Biotronik is headquartered in Berlin, Germany, and represented in over 100 countries. OMEICOS had implemented Biotronik’s insertable cardiac monitor BioMonitor 2 into the study design of the Phase 2 clinical trial of OMT-28 in persistent Atrial Fibrillation to accurately detect and monitor arrhythmias.